Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers

European Journal of Clinical Pharmacology

Volumn 64, Issue 11, 2008, Pages 1101-1109

  Faessel, H M ^a   Burstein, A H ^a   Troutman, M D ^a   Willavize, S A ^a   Rohrbacher, K D ^a   Clark, D J ^a  

^a PFIZER INC   (United States)

Author keywords

Digoxin; Drug drug interaction; Smoking cessation; Varenicline

Indexed keywords

CYCLOSPORIN A; DIGOXIN; ERYTHROMYCIN; GLYCOPROTEIN P; KETOCONAZOLE; MANNITOL; METOPROLOL; PLACEBO; VARENICLINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CROSS REACTIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; KIDNEY CLEARANCE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SMOKING; SMOKING CESSATION; STEADY STATE; TOBACCO DEPENDENCE;

ADOLESCENT; ADULT; AREA UNDER CURVE; BENZAZEPINES; CACO-2 CELLS; DIGOXIN; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; P-GLYCOPROTEIN; QUINOXALINES; SMOKING CESSATION;

EID: 55349087223     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0530-6     Document Type: Article

References (40)

1. World Health Report (2004) Reducing risks, promoting healthy life. World Health Organization, Geneva
2. Kannel WB (1977) Importance of hypertension as a major risk factor in cardiovascular disease. In: Genest J, Koiw E, Kuchel O (eds) Hypertension: physiopathology and treatment. McGraw-Hill, New York
3. Novotny TE, Giovino GA (1998) Tobacco use. In: Brownson RC, Remington PL, Davis JR (eds) Chronic disease epidemiology and control. American Public Health Association, Washington DC
4. R Puranik DS Celermajer 2003 Smoking and endothelial function Prog Cardiovasc Dis 45 443 458
5. S Tsiara M Elisaf DP Mikhailidis 2003 Influence of smoking on predictors of vascular disease Angiology 54 507 530
6. HC McGill CA McMahan GT Malcom OC Oalmann JP Strong 1997 Effects of serum lipoproteins and smoking on atherosclerosis in young men and women The PDAY research group. Pathobiological determinants of atherosclerosis in youth. Arterioscler Thromb Vasc Biol 17 95 106
7. AV Chobanian GL Bakris HR Black 2003 The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2560 2572
8. G De Backer E Ambrosioni K Borch-Johnsen 2003 European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts) Eur J Cardiovasc Prev Rehabil 10 S1 S10
9. H Rollema LK Chambers JW Coe 2007 Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid Neuropharmacology 52 985 994
10. JW Coe PR Brooks MG Vetelino 2005 Varenicline: a novel, potent, and α4β2 selective nicotinic receptor partial agonist as an aid for smoking cessation J Med Chem 48 3474 3477
11. C Oncken E Watsky KR Reeves R Anziano the Varenicline Study Working Group 2005 Efficacy and safety of the novel selective nicotinic receptor partial agonist varenicline for smoking cessation J Am Coll Cardiol 45 381A
12. D Gonzales SI Rennard M Nides 2006 Varenicline, an α4β2 nicotinic acetylcholine partial receptor agonist, vs. sustained-release bupropion and placebo for smoking cessation. A randomized controlled trial JAMA 296 47 55
13. DE Jorenby JT Hays NA Rigotti 2006 Efficacy of varenicline, an α4β2 nicotinic acetylcholine partial receptor agonist, vs. placebo or sustained-release bupropion for smoking cessation. A randomized controlled trial JAMA 296 56 63
14. FI Marcus 1985 Pharmacokinetic interactions between digoxin and other drugs J Am Coll Cardiol 5 82A 90A
15. SM Rodin BF Johnson 1988 Pharmacokinetic interactions with digoxin Clin Pharmacokinet 15 227 244
16. Reuning RH, Geraets DR, Rocci ML, Vlasses PH (1992) Digoxin. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics. Principles of therapeutic drug monitoring, chapter 20. 3rd edn. Applied Therapeutics, Vancouver, pp 1-48
17. B Greiner M Eichelbaum P Fritz HP Kreichgauer O von Richter J Zundler HK Kroemer 1999 The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin J Clin Invest 104 147 153
18. RA Boyd RH Stern BH Stewart 2000 Atorvastatin co-administration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein- mediated secretion J Clin Pharmacol 40 91 98
19. K Westphal A Weinbrenner M Zschiesche 2000 Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein Clin Pharmacol Ther 68 6 12
20. MF Fromm RB Kim CM Stein GR Wilkinson DM Roden 1999 Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine Circulation 99 552 557
21. M Verschraagen CH Koks JH Schellens JH Beijnen 1999 P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil Pharmacol Res 40 301 306
22. JM Kovarik L Rigaudy M Guerret C Gerbeau KL Rost 1999 Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin Clin Pharmacol Ther 66 391 400
23. Y Kurata I Ieiri M Kimura 2002 Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein Clin Pharmacol Ther 72 209 219
24. HM Faessel BJ Smith MA Gibbs JS Gobey DJ Clark AH Burstein 2006 Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers J Clin Pharmacol 46 991 998
25. HM Faessel MA Gibbs DJ Clark K Rohrbacher M Stolar AH Burstein 2006 Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers J Clin Pharmacol 46 1439 1448
26. AH Burstein T Fullerton DJ Clark HM Faessel 2006 Pharmacokinetics, safety and tolerability following single and multiple oral doses of varenicline in elderly smokers J Clin Pharmacol 46 1234 1240
27. RS Obach AE Reed-Hagen SS Krueger 2005 Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro Drug Metab Dispos 34 121 130
28. DW Cockcroft MH Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41
29. J Stangier CA Su MG Hendriks 2000 The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers J Clin Pharmacol 40 1373 1379
30. BD Zussman J Kelly RD Murdoch P Schofield DM Webber 2001 Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin Clin Ther 23 921 931
31. MD Troutman DR Thakker 2003 Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers Pharm Res 20 1200 1209
32. MD Troutman DR Thakker 2003 Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium Pharm Res 20 1210 1224
33. JP Keogh JR Kunta 2006 Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein Eur J Pharm Sci 27 543 554
34. J Gao O Murase RL Schowen J Aube RT Borchardt 2001 A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells Pharm Res 18 171 176
35. RL Walsky AV Astuccio RS Obach 2006 Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6 J Clin Pharmacol 46 1426 1438
36. J Hunter BH Hirst NL Simmons 1993 Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers Pharm Res 10 743 749
37. ME Cavet M West NL Simmons 1996 Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells Br J Pharmacol 118 1389 1396
38. J Rautio JE Humphreys LO Webster 2006 In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates Drug Metab Dispos 34 786 792
39. AH Burstein DJ Clark M O'Gorman 2007 Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin. An in vivo and in vitro study J Clin Pharmacol 47 1421 1429
40. B Feng RS Obach AH Burstein DJ Clark SM De Morais HM Faessel 2008 Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study Clin Pharmacol Ther 83 5 567 576